Breakfast with the Investigators: Urothelial Bladder Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Which of the following best describes TAR-200?**
   a. Internal radioactive implant
   b. Wafer-based chemotherapy implant
   c. Intravesical drug delivery system for gemcitabine

2. **Preliminary results from the Phase II SunRISe-1 trial revealed the greatest complete response rate with which of the following monotherapies in patients with bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer?**
   a. Cetrelimab
   b. TAR-200
   c. Complete response rates were equivalent for both arms

3. **In the Phase III CheckMate 274 trial, adjuvant nivolumab reduced the risk of disease progression or death in which patients with high-risk muscle-invasive bladder cancer?**
   a. PD-L1 ≥1
   b. Intention-to-treat population
   c. Both a and b
   d. Neither a nor b

4. **The combination of enfortumab vedotin and pembrolizumab recently received accelerated FDA approval in which of the following patient populations?**
   a. Patients with platinum-refractory disease
   b. Patients with muscle-invasive disease
   c. Cisplatin-ineligible patients with locally advanced or metastatic disease
   d. Cisplatin-eligible patients with locally advanced or metastatic disease

5. **Disitamab vedotin is an antibody-drug conjugate targeting which of the following?**
   a. Nectin-4
   b. HER2
   c. FGFR3
   d. TROP2